Acquisitions and biotechs are moving this morning

What you need to know                                                                                                                                                                                                                                                                                                                                                                                                                 September 23, 2024 *sponsored by Stock Earnings Good day, 360! Here are some of our top movers today. And don’t forget to join us in [Market Masters]( - — Jeff B will be LIVE at 11am EST for his weekly Bullseye rundown 🔥. Be there… and be the best prepared trader on the Street! FOCUS LIST🔎 SGN - Up over 44% in the pre-market after announcing update to financial position and synergies expected from its acquisition of Swifty Global that’s expected to drive accelerated revenue growth, cost savings, and global expansion BDTX - Up over 38% in pre after announcing initial Phase 2 data demonstrating robust anti-tumor activity of BDTX-1535 ELEV - Up over 10% in pre after announcing it has received fast track designation from the FDA for EO-3021 for the treatment of adult patients with advanced or Metastatic Gastric or Gastroesophageal Junction Cancer expressing Claudin 18.2 JUST DROPPED Limited Seats Available at These BLOWOUT Prices: Use Code 70%OFF (one word) and hit APPLY [Next $2000 Small Account Journey Starts Soon!]( HOTLIST🔥 SGN - Up over 44% in the pre-market after announcing update to financial position and synergies expected from its acquisition of Swifty Global that’s expected to drive accelerated revenue growth, cost savings, and global expansion Signing Day Sports Inc. (SGN) operates a sports recruitment platform in the United States. The company offers Signing Day Sports, a sports recruitment platform that helps athletes get discovered and recruited by coaches and recruiters for various sports. In the pre-market this morning, the [company announced]( an update regarding its financial position and its plans to acquire Dear Cashmere Group Holding Company (OTC:DRCR), doing business as Swifty Global (“Swifty”), highlighting the strategic and financial synergies that are expected to drive accelerated growth and operational efficiency for both companies. Signing Day Sports convertible notes are now fully extinguished, removing $0.6 million of liabilities from its balance sheet and marking major step towards restructuring for growth. Swifty achieved revenues of over $128 million and a net profit of approximately $2.44 million for the fiscal year ended December 31, 2023, despite significant investments of nearly $3.1 million in software development and licensing. SGN traded up over 44% in the pre-market in reaction to the update. The $0.4 area acted as support last week and now becomes a potential level of resistance. Above it, targets to the upside are $0.50, $0.60, $0.70 and then $0.7645. Below $0.40, targets to the downside are $0.30 and then a gap to fill at $0.26. BDTX - Up over 38% in pre after announcing initial Phase 2 data demonstrating robust anti-tumor activity of BDTX-1535 Black Diamond Therapeutics Inc. (BDTX) is a clinical-stage oncology medicine company that focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Overnight, the [company reported]( initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC). Highlights include: BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations Encouraging durability with DOR of approximately 8 months or more for first 3 patients with a PR; 14 of 19 patients remain on treatment The stock traded up over 38% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $7.35. Beyond that, $7.66, $8 and $8.75 come into play. Below $7.35, targets to the downside are $6.58, $6.45, $6.29, $6 and then a gap to fill at $5.50, $5.15 and then a gap to fill at $4.76, *sponsored by Stock Earnings Gold’s Booming… But These Gold Stocks are Doing Even Better! Physical gold protects your wealth, but miners are where the real action is. Here are 10 gold stocks in particular to watch… [Claim your free report now]( ELEV - Up over 10% in pre after announcing it has received fast track designation from the FDA for EO-3021 for the treatment of adult patients with advanced or Metastatic Gastric or Gastroesophageal Junction Cancer expressing Claudin 18.2 Elevation Oncology Inc. (ELEV) is an oncology company that focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. In the pre-market this morning, the [company announced]( that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy. Fast Track is a process designed by the FDA to facilitate the development and expedite the review of therapeutic candidates intended to treat serious or life-threatening conditions, for which nonclinical or clinical data demonstrate the potential to address unmet medical needs. The stock traded up over 10% in the pre-market in reaction to the news. Buyers were found around the $0.60 area and that will be an important level to watch. Above it, targets to the upside are $0.68, $0.70, and then the pre-market high at $0.7399. Beyond that, $0.80, $0.83 and then $1 comes into play. Below $0.60, targets to the downside are $0.5859, $0.58, $0.54 and $0.51. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at *Sponsored content: We’re a proud affiliate for Stock Earnings, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](